fluticasone/vilanterol (Breo Ellipta)
Jump to navigation
Jump to search
Indications
- combination inhaler therapy for treatment of
* no improvement in mortality[4]
* safe for patients with cardiovascular disease[4]
Contraindications
- not FDA-approved to treat asthma in children or adolescents or to treat acute bronchospasm[2]
Dosage
- once a day dry powder
Mechanism of action
- combination of inhaled glucocorticoid (fluticasone) with long-acting beta-2 adrenergic receptor agonist (vilanterol)
More general terms
References
- ↑ 1.0 1.1 Physician's First Watch, May 1, 2013 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
FDA News Release: May 10, 2013 FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease - ↑ 2.0 2.1 2.2 GlaxoSmithKline News Release. April 30, 2015 FDA approves BREO ELLIPTA<TM> for the treatment of adults with asthma in the US. http://us.gsk.com/en-us/media/press-releases/2015/fda-approves-breo-ellipta-for-the-treatment-of-adults-with-asthma-in-the-us/
- ↑ Kerwin EM, Scott-Wilson C, Sanford L et al A randomised trial of fluticasone furoate/vilanterol (50/25 ug; 100/25 ug) on lung function in COPD. Respir Med. 2013 Apr;107(4):560-9 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23352226
- ↑ 4.0 4.1 4.2 Vestbo J, Anderson JA, Brook RD et al Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016 Apr 30;387(10030):1817-26. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27203508
Brusselle G. Vilanterol fluticasone and mortality in comorbid COPD GOLD B. Lancet. 2016 Apr 30;387(10030):1791-2. Epub 2016 Apr 28. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27203487 - ↑ 5.0 5.1 Vestbo J, Leather D, Diar Bakerly N et al Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. N Engl J Med. Sept 4, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27593504 Free Article <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1608033
- ↑ 6.0 6.1 Woodcock A, Vestbo J, Bakerly ND et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: An open-label, parallel group, randomised controlled trial. Lancet 2017 Sep 10; PMID: https://www.ncbi.nlm.nih.gov/pubmed/28903864
Gibson P. Effectiveness trials in asthma: Time to SaLSA? Lancet 2017 Sep 10 PMID: https://www.ncbi.nlm.nih.gov/pubmed/28903863